TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUMATIC ACID
申请人:Neuren Pharmaceuticals Limited
公开号:US20150224164A1
公开(公告)日:2015-08-13
This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.
本发明提供了使用甘氨酰-2-甲基脯氨酰-谷氨酸(G-2-MePE)及其类似物治疗自闭症谱系障碍(ASD)的化合物、组合物和方法。自闭症谱系障碍包括自闭症、孟德尔综合征、亚斯伯格综合征、儿童退化性障碍、广泛性发育障碍-未特指(PDD-NOS)、脆性X综合征和雷特综合征。含有该化合物的组合物包括水溶性配方、水-油微乳、水-油粗乳、水-油液晶、纳米胶囊、片剂和口服凝胶。本发明的化合物和组合物可以通过静脉注射、脑室注射、皮下注射或口服给药,并且可以有效治疗神经退行性疾病、促进神经功能、治疗癫痫和其他ASD症状,并可以延长患有自闭症谱系障碍的动物,包括人类的寿命。